stoxline Quote Chart Rank Option Currency Glossary
  
Sonoma Pharmaceuticals, Inc. (SNOA)
0.1574  0 (0%)    04-23 11:20
Open: 0.1574
High: 0.1574
Volume: 20,600
  
Pre. Close: 0.1574
Low: 0.157
Market Cap: 2(M)
Technical analysis
2024-04-23 10:51:10 AM
Short term     
Mid term     
Targets 6-month :  0.19 1-year :  0.22
Resists First :  0.16 Second :  0.18
Pivot price 0.16
Supports First :  0.12 Second :  0.1
MAs MA(5) :  0.15 MA(20) :  0.16
MA(100) :  0.16 MA(250) :  0.56
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  29.7 D(3) :  33.7
RSI RSI(14): 49.6
52-week High :  1.51 Low :  0.11
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SNOA ] has closed above bottom band by 36.9%. Bollinger Bands are 34.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.16 - 0.16 0.16 - 0.16
Low: 0.15 - 0.15 0.15 - 0.15
Close: 0.16 - 0.16 0.16 - 0.16
Company Description

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

Headline News

Tue, 09 Apr 2024
Sonoma Pharmaceuticals expands wound therapy line - Investing.com India

Thu, 04 Apr 2024
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing ... - Yahoo Finance

Thu, 28 Mar 2024
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences - Yahoo Finance

Sat, 10 Feb 2024
Sonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Thu, 08 Feb 2024
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results - Yahoo Finance

Tue, 23 Jan 2024
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 16 (M)
Shares Float 15 (M)
Held by Insiders 1.5 (%)
Held by Institutions 1.9 (%)
Shares Short 30 (K)
Shares Short P.Month 121 (K)
Stock Financials
EPS -0.82
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.49
Profit Margin -41.3 %
Operating Margin -26.9 %
Return on Assets (ttm) -19.5 %
Return on Equity (ttm) -82.9 %
Qtrly Rev. Growth 6.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.78
EBITDA (p.s.) -0.28
Qtrly Earnings Growth 0 %
Operating Cash Flow -5 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -0.2
PEG Ratio 0
Price to Book value 0.32
Price to Sales 0.19
Price to Cash Flow -0.5
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android